Non-alcoholic Fatty Liver Disease

• 

  Subject Areas on Research

  • A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. 
  • A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis. 
  • A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. 
  • A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. 
  • A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. 
  • A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. 
  • Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. 
  • Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. 
  • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. 
  • Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. 
  • Association between puberty and features of nonalcoholic fatty liver disease. 
  • Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. 
  • Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. 
  • Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. 
  • Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. 
  • Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. 
  • Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. 
  • CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis. 
  • Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. 
  • Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease. 
  • Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. 
  • Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. 
  • Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. 
  • Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. 
  • Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. 
  • Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. 
  • Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. 
  • Comment on: impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. 
  • Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. 
  • Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. 
  • Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. 
  • Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. 
  • Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 
  • Current status of fibrosis markers. 
  • DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. 
  • De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. 
  • Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. 
  • Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. 
  • Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. 
  • Dietary and commercialized fructose: Sweet or sour? 
  • Direct effects of thyroid hormones on hepatic lipid metabolism. 
  • Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. 
  • Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice? 
  • Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply. 
  • Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. 
  • Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. 
  • Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
  • Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21. 
  • Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. 
  • Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. 
  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. 
  • Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. 
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. 
  • Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. 
  • Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. 
  • Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. 
  • Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. 
  • Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. 
  • HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease. 
  • Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. 
  • Hedgehog pathway and pediatric nonalcoholic fatty liver disease. 
  • Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity. 
  • Hepatic HKDC1 Expression Contributes to Liver Metabolism. 
  • Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk. 
  • Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. 
  • Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. 
  • Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. 
  • High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. 
  • Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. 
  • Hormone signaling and fatty liver in females: analysis of estrogen receptor α mutant mice. 
  • Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. 
  • Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. 
  • Implication of gut microbiota in nonalcoholic fatty liver disease. 
  • Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. 
  • Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. 
  • Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy. 
  • Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis. 
  • Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. 
  • Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis. 
  • Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. 
  • Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. 
  • Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. 
  • Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. 
  • Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. 
  • Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. 
  • M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice. 
  • MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. 
  • Measuring acetyl-CoA and acetylated histone turnover in vivo: Effect of a high fat diet. 
  • Mechanisms of disease progression in NASH: new paradigms. 
  • Metabolic liver disease - what's in a name? 
  • Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. 
  • Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. 
  • Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver. 
  • Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. 
  • Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. 
  • NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. 
  • NAFLD and extrahepatic cancers: have a look at the colon. 
  • NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. 
  • NAFLD, NASH and liver cancer. 
  • NASH in HIV. 
  • NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. 
  • NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 
  • NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. 
  • No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. 
  • Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? 
  • Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. 
  • Nonalcoholic Fatty Liver Disease and the Gut Microbiome. 
  • Nonalcoholic Fatty Liver Disease. 
  • Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. 
  • Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. 
  • Nonalcoholic Steatohepatitis. 
  • Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context. 
  • Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. 
  • Nonalcoholic fatty liver disease: another leap forward. 
  • Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. 
  • Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. 
  • Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone. 
  • Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. 
  • Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds. 
  • Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. 
  • Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. 
  • Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. 
  • Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Re-Evaluating Age Limits in Transplantation Consortium. 
  • PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. 
  • Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. 
  • Pathogenesis of Nonalcoholic Steatohepatitis. 
  • Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. 
  • Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. 
  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. 
  • Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. 
  • Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. 
  • Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. 
  • Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine. 
  • Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis. 
  • Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. 
  • Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. 
  • Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. 
  • Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. 
  • Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. 
  • Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. 
  • Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. 
  • Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. 
  • Reply to Kim et al. 
  • Reply. 
  • Reply. 
  • Reply. 
  • Reply. 
  • Reply: To PMID 24849310. 
  • Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. 
  • Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. 
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 
  • Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. 
  • Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 
  • Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. 
  • Role of Hedgehog Signaling Pathway in NASH. 
  • Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. 
  • Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. 
  • Screening for metabolic and reproductive complications in obese children and adolescents. 
  • Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. 
  • Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. 
  • Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. 
  • Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. 
  • Sugar sweetened beverages and fatty liver disease: Rising concern and call to action. 
  • Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. 
  • Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers. 
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. 
  • TRPV4 activation of endothelial nitric oxide synthase resists nonalcoholic fatty liver disease by blocking CYP2E1-mediated redox toxicity. 
  • Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. 
  • Testing for Nonalcoholic Fatty Liver Disease. 
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 
  • The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. 
  • The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. 
  • The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. 
  • The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The hedgehog pathway in nonalcoholic fatty liver disease. 
  • The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. 
  • The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. 
  • Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis? 
  • Towards a definite mouse model of NAFLD. 
  • Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. 
  • Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. 
  • Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis. 
  • Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. 
  • Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. 
  • Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. 
  • Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. 
  • Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. 
• 

  Keywords of People

  • Alexopoulos, Anastasia Stefania, Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition
  • Liao, Tzu-chieh, Student, Immunology
  • Wong, Chi Wut, Student, Pharmacology & Cancer Biology